Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brazil launches major study to map ovarian cancer treatment gaps

NCT ID NCT07167433

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 03, 2026 · Updated 7 times

Summary

This observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insights to set quality standards for ovarian cancer care across the country.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help improve ovarian cancer treatment guidelines and care quality in Brazil.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly test new therapies or provide immediate patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study base consists of patients newly diagnosed with ovarian cancer across stages IA to IVB, and those with persistent or recurrent disease, diagnosed from January 2021 onwards.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years old; * Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021; * Irrespective of histology Exclusion Criteria: * Borderline tumors; * Pregnancy; * Synchronous tumor or second primary in the last 5 years (except thyroid cancer and non-melanoma skin cancer);

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Barretos/SP, Brazil

  • Research Site

    RECRUITING

    Belo Horizonte/MG, Brazil

  • Research Site

    RECRUITING

    Bras lia/DF, Brazil

  • Research Site

    RECRUITING

    Curitiba/PR, Brazil

  • Research Site

    RECRUITING

    Goi nia/GO, Brazil

  • Research Site

    RECRUITING

    Joao Pessoa/PB, Brazil

  • Research Site

    RECRUITING

    Natal/RN, Brazil

  • Research Site

    RECRUITING

    Porto Alegre/RS, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    Porto Alegre/RS, Brazil

  • Research Site

    RECRUITING

    Recife/PE, Brazil

  • Research Site

    RECRUITING

    Rio Branco/AC, Brazil

  • Research Site

    RECRUITING

    Rio de Janeiro/RJ, Brazil

  • Research Site

    RECRUITING

    S O Jose Dos Campos/SP, Brazil

  • Research Site

    RECRUITING

    S O Paulo/SP, Brazil

  • Research Site

    RECRUITING

    Salvador/BA, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.